Which company manufactures Datopotamab?

Datopotamab (Datopotamab), as an antibody-conjugated drug that has attracted much attention in recent years, was originally developed by Japan's Daiichi Sankyo Co., Ltd. and has launched in-depth cooperation with AstraZeneca on a global scale. This drug belongs to the ADC technology platform targeting TROP2 and is an extension of Daiichi Sankyo’s independent DXd linker-cytotoxic small molecule system. This platform has become a highly active technical route in the field of international oncology research and development, making dedabrotomab highly valued by major regulatory agencies and academia during the research and development stage.

Judging from overseas data, Daiichi Sankyo has built a complete R&D matrix around ADCs in recent years, of which Datopotamab deruxtecan is regarded as the core representative of its "second-generation TROP2-targeted ADC". Compared with early treatment strategies targeting TROP2, this drug has been optimized in terms of linker stability, drug release mechanism, and tissue selectivity, aiming to reduce systemic toxicity and improve drug penetration efficiency in solid tumors. After AstraZeneca joins, it will have stronger power in filing, production and global commercialization, and it will also accelerate its advancement in the US, EU and Asia-Pacific markets.

Dedabrotomab's production system relies on Daiichi Sankyo's many years of experience in biomacromolecule manufacturing and adopts high-standard protein engineering and conjugation technology. Its quality control, from antibody construction, drug binding ratio (DAR) to final finished product, has passed continuous verification. Overseas literature points out that the product's supply chain covers biomanufacturing bases in Japan, the United States and Europe, providing relatively sufficient technical reserves for future production capacity expansion after launch.

With the continuous development of global anti-HER2 and TROP2 targeting fields, the research and development of dabrotuzumab is also pushing the indications of ADC to extend to inoperable advanced solid tumors, triple negative breast cancer and non-small cell lung cancer.

Reference materials:https://dailymed.nlm.nih.gov/